Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according ...
Kidney disease related mortality: Trends and disparities among patients with multiple myeloma. Demographic and regional trends in multiple myeloma and cardiovascular disease–related mortality among ...
Impact of declining renal function on multiple myeloma (MM) mortality in the U.S. (1999-2023): A regression analysis using the CDC WONDER database. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Hosted on MSN
Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...
So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...
January 13, 2009 — Tandem autologous hematopoietic cell transplantation (AHCT) does not appear to improve overall survival or event-free survival in patients with multiple myeloma, according to a meta ...
The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results